Literature DB >> 32931397

Reply to M. Hertzberg et al.

Mark Roschewski1, Kieron Dunleavy1, Wyndham H Wilson1.   

Abstract

Year:  2020        PMID: 32931397      PMCID: PMC7605395          DOI: 10.1200/JCO.20.02290

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

2.  Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Authors:  Vincent Ribrag; Serge Koscielny; Jacques Bosq; Thibaut Leguay; Olivier Casasnovas; Luc-Mathieu Fornecker; Christian Recher; Hervé Ghesquieres; Franck Morschhauser; Stéphane Girault; Steven Le Gouill; Mario Ojeda-Uribe; Clara Mariette; Jerome Cornillon; Guillaume Cartron; Veronique Verge; Catherine Chassagne-Clément; Hervé Dombret; Bertrand Coiffier; Thierry Lamy; Hervé Tilly; Gilles Salles
Journal:  Lancet       Date:  2016-04-11       Impact factor: 79.321

3.  DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?

Authors:  Mark Hertzberg; David J L Joske; Maher K Gandhi
Journal:  J Clin Oncol       Date:  2020-09-15       Impact factor: 44.544

4.  Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

Authors:  Mark Roschewski; Kieron Dunleavy; Jeremy S Abramson; Bayard L Powell; Brian K Link; Prapti Patel; Philip J Bierman; Deepa Jagadeesh; Ronald T Mitsuyasu; David Peace; Peter R Watson; Wahid T Hanna; Christopher Melani; Andrea N Lucas; Seth M Steinberg; Stefania Pittaluga; Elaine S Jaffe; Jonathan W Friedberg; Brad S Kahl; Richard F Little; Nancy L Bartlett; Michelle A Fanale; Ariela Noy; Wyndham H Wilson
Journal:  J Clin Oncol       Date:  2020-05-26       Impact factor: 44.544

5.  Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

Authors:  Nicholas J Short; Hagop M Kantarjian; Heidi Ko; Joseph D Khoury; Farhad Ravandi; Deborah A Thomas; Guillermo Garcia-Manero; Maria Khouri; Jorge E Cortes; William G Wierda; Srdan Verstovsek; Zeev Estrov; Alessandra Ferrajoli; Philip A Thompson; Sherry Pierce; Susan M O'Brien; Elias Jabbour
Journal:  Am J Hematol       Date:  2017-04-18       Impact factor: 10.047

6.  Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.

Authors:  Dieter Hoelzer; Jan Walewski; Hartmut Döhner; Andreas Viardot; Wolfgang Hiddemann; Karsten Spiekermann; Hubert Serve; Ulrich Dührsen; Andreas Hüttmann; Eckhard Thiel; Jolanta Dengler; Michael Kneba; Markus Schaich; Ingo G H Schmidt-Wolf; Joachim Beck; Bernd Hertenstein; Albrecht Reichle; Katarzyna Domanska-Czyz; Rainer Fietkau; Heinz-August Horst; Harald Rieder; Stefan Schwartz; Thomas Burmeister; Nicola Gökbuget
Journal:  Blood       Date:  2014-10-30       Impact factor: 22.113

7.  An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.

Authors:  G M Mead; M R Sydes; J Walewski; A Grigg; C S Hatton; N Pescosta; C Guarnaccia; M S Lewis; J McKendrick; S P Stenning; D Wright; P Norbert
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

8.  Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.

Authors:  Andrew M Evens; Alexey Danilov; Deepa Jagadeesh; Amy Sperling; Seo-Hyun Kim; Ryan Vaca; Catherine Wei; Daniel Rector; Suchitra Sundaram; Nishitha Reddy; Yong Lin; Umar Farooq; Christopher D'Angelo; David A Bond; Stephanie Berg; Michael C Churnetski; Amandeep Godara; Nadia Khan; Yun Kyong Choi; Maryam Yazdy; Emma Rabinovich; Gaurav Varma; Reem Karmali; Agrima Mian; Malvi Savani; Madelyn Burkart; Peter Martin; Albert Ren; Ayushi Chauhan; Catherine Diefenbach; Allandria Straker-Edwards; Andreas K Klein; Kristie A Blum; Kirsten Marie Boughan; Scott E Smith; Brad M Haverkos; Victor M Orellana-Noia; Vaishalee P Kenkre; Adam Zayac; Jeremy Ramdial; Seth M Maliske; Narendranath Epperla; Parameswaran Venugopal; Tatyana A Feldman; Stephen D Smith; Andrzej Stadnik; Kevin A David; Seema Naik; Izidore S Lossos; Matthew A Lunning; Paolo Caimi; Manali Kamdar; Neil Palmisiano; Veronika Bachanova; Craig A Portell; Tycel Phillips; Adam J Olszewski; Juan Pablo Alderuccio
Journal:  Blood       Date:  2021-01-21       Impact factor: 22.113

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.